# McKesson (MCK) Q1 FY2027 earnings

Results filed 2026-08-05 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/mck/2027-q1/
Press release and documents: https://www.sec.gov/Archives/edgar/data/927653/000092765326000232/0000927653-26-000232-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

McKesson named its future standalone Medical-Surgical business Wellverse and sold about 13% of it to Apollo Funds for $1.25 billion, advancing the planned separation.

McKesson's growth this quarter came from specialty medicines and oncology. North American Pharmaceutical gained from higher prescription volumes, especially specialty products sold to health systems and strategic accounts. Oncology & Multispecialty grew on provider solutions, specialty distribution and acquisitions. Prescription Technology Solutions saw higher demand for access solutions. Medical-Surgical Solutions grew across alternate sites of care but earned less on product mix and one-time administrative costs.
Management is concentrating on oncology, multispecialty and biopharma services while preparing to spin off Medical-Surgical Solutions as Wellverse. The company funded the separation with a $2.25 billion Term Loan B and the Apollo investment. It also plans about $5.0 billion of share repurchases this year. The main risk is that the separation may not close on the planned terms or timeline, or deliver the intended benefits.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenues | $105.4 billion | up 8% from a year ago | GAAP |
| Net income attributable to McKesson | $614 | down 22% from $784 a year ago | GAAP |
| Diluted EPS | $5.15 | down $1.10 from a year ago | GAAP |
| Adjusted EPS | $9.93 | up 20% from a year ago | non-GAAP |
| Operating income | 1,319 | up 27% from a year ago | GAAP |
| Net cash used in operating activities | $(220) | compared with $(918) a year ago | GAAP |
| Free cash flow | $(372) | compared with $(1,107) a year ago | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| North American Pharmaceutical revenue | $86.8 billion | up 5% |
| Oncology & Multispecialty revenue | $14.2 billion | up 33% |
| Prescription Technology Solutions revenue | $1.6 billion | up 9% |
| Medical-Surgical Solutions revenue | $2.8 billion | up 4% |
| Oncology & Multispecialty adjusted segment operating profit | $405 million | up 41% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted EPS | fiscal 2027 | $44.20 to $45.00 |
| Revenue growth | fiscal 2027 | 5% to 9% growth |
| Adjusted operating profit growth | fiscal 2027 | 9% to 13% growth |
| Effective tax rate | fiscal 2027 | 18% to 19% |
| Free cash flow | fiscal 2027 | $4.5 to $4.9 billion |

## Key takeaways

1. **Medical-Surgical business gets name and outside investor** McKesson unveiled Wellverse as the name of the future standalone Medical-Surgical Solutions business. It also sold about 13% of the unit to Apollo Funds for $1.25 billion, which moves the planned separation forward.
2. **Specialty medicines drive pharmaceutical distribution growth** North American Pharmaceutical gained from higher specialty product volumes, particularly to health systems and strategic accounts, and from the timing of new product launches. Branded pharmaceuticals contributed less.
3. **Oncology & Multispecialty is the fastest-growing segment** Growth came from provider solutions and specialty distribution, including contributions from acquisitions. Management says it will make focused investments to speed up oncology, multispecialty and biopharma services.
4. **Access solutions demand lifts technology segment** Prescription Technology Solutions saw higher demand for access solutions and more prescription volume in third-party logistics. Restructuring and impairment charges fell mainly in this segment.
5. **Medical-Surgical earned less despite growth in alternate sites** Revenue grew across alternate sites of care, led by specialty pharmaceuticals and helped by the extended care channel. Adjusted segment operating profit fell 20% on product mix and one-time administrative expenses.

## Questions

**What is Wellverse?** Wellverse is the name McKesson announced on August 5, 2026 for the future standalone Medical-Surgical Solutions business. It reflects continued progress toward the planned separation.
**Who is investing in McKesson's Medical-Surgical Solutions business?** On June 1, 2026, McKesson sold an approximately 13% minority interest in the business to Apollo Funds for $1.25 billion. On June 9 it also set up a $2.25 billion secured Term Loan B in support of the separation.
**Where is McKesson's demand growth coming from?** Growth is coming from specialty products sold to health systems and strategic accounts, oncology provider solutions and specialty distribution including acquisitions, and access solutions in Prescription Technology Solutions.
**Which business is under pressure?** Medical-Surgical Solutions saw adjusted segment operating profit fall 20%, on product mix and one-time administrative expenses, partly offset by the extended care channel.
**What did McKesson change in its outlook and capital plans?** It raised fiscal 2027 adjusted EPS guidance to $44.20 to $45.00 from $43.80 to $44.60. It plans about $5.0 billion of share repurchases this year and raised the quarterly dividend 15% to $0.94 per share.

## Slides and investor documents

- [Presentation](https://s24.q4cdn.com/128197368/files/doc_financials/2027/q1/MCK-Q1-FY27-Presentation_FINAL.pdf) (Slide deck)
- [Transcript](https://s24.q4cdn.com/128197368/files/doc_financials/2027/q1/260805-MCK-Q1FY27-Earnings-Call-Transcript-1.pdf) (Company's official transcript)
- [Webcast](https://events.q4inc.com/attendee/695892792) (Webcast replay)
- [Release](https://s24.q4cdn.com/128197368/files/doc_financials/2027/q1/MCK-Q1-FY27-Earnings-Release_FINAL.pdf) (Document)
- [10-Q](https://s24.q4cdn.com/128197368/files/doc_financials/2027/q1/MCK_10Q_6-30-2026-FINAL.pdf) (Document)

